Most Favored Nation Drug Pricing Program Expanded to States

All 50 states have joined a program to align Medicaid drug prices with those paid by comparable developed nations.

Updated on Oct. 1, 2026 in Healthcare

Bold flat-color editorial illustration of pharmacy vials and a metal weight, symbolizing the alignment of drug pricing standards. — All 50 states have joined the Most Favored Nation drug pricing program, a federal initiative designed to align Medicaid costs with international benchmarks. AI Illustration. Upload story photo >

Live Poll

Do you believe state and federal government efforts to negotiate drug prices will lower your costs?

President Donald Trump announced that all 50 states, the District of Columbia, and Puerto Rico are participating in the Most Favored Nation drug pricing program. The initiative is projected to save Medicaid programs $64 billion and state governments $28 billion over the next decade.

Why it matters

The program alters procurement strategies for state-level healthcare administrators by tying reimbursement rates to international benchmarks. By aligning U.S. prices with those in other developed countries, the administration seeks to reduce the financial burden on state budgets like Mississippi's, which spends roughly $700 million annually on Medicaid drugs.

The program covers 90% of the branded U.S. market, with 26 drugmakers agreeing to the new pricing structure. Beyond the $64 billion in Medicaid savings, the administration projects total national savings of $600 billion.

The players

Donald Trump

The current President of the United States.

The details

The program requires U.S. drug prices to match the lowest costs paid by comparable developed nations, fundamentally changing the baseline for state Medicaid contracts. Participating states receive the operational flexibility to negotiate prices and implement the model. This effort complements the $50 billion Rural Healthcare Transformation Fund and the ongoing operations of the TrumpRx platform, which has already delivered $700 million in total savings.

September 25, 2026: President Trump and governors met at the White House to announce the program.
Next decade: The period over which the projected $64 billion in Medicaid savings is expected to accrue.

Market Landscape

This move marks a major expansion of the Most Favored Nation drug pricing program, setting a new precedent for federal-state coordination on pharmaceutical costs. It follows the administration's pattern of utilizing executive-led platforms like TrumpRx to drive down pricing through consolidated market leverage.

Operators in the healthcare sector should monitor how this pricing floor affects existing vendor contracts and supply chain negotiations. State-level providers and Medicaid-reliant facilities should prepare for shifts in reimbursement rates as states adjust their procurement strategies to match the new pricing model.

The takeaway

The nationwide rollout signals a shift toward international price parity for Medicaid-funded pharmaceuticals. Business operators should audit their current pharmaceutical spend and review potential contract renegotiation windows that may arise as states integrate this pricing framework.